Under the agreement, ZBx can exercise its option during a period which starts 90 days from, and expires 120 days after, the effective date of the Option.
If ZBx exercises such option, Ambrilia will be entitled to obtain up to a total of $50,000 upon signing of a definitive agreement and achievement of sales milestones, as well as royalties on sales and a percentage share of proceeds from any sublicenses or sale of PSP-94 by ZBx.
Additionally, ZBx is expected to take up all future costs linked with the further development, manufacturing and commercialization of PSP-94.